

Reversal and Reinitiation of Anticoagulation

(2024-2027)

REFERENCES

1. Linkins LA, Choi PT, Douketis JD. Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism. *Ann Intern Med.* 2003;139(11):893-900. doi:10.7326/0003-4819-139-11-200312020-00007
2. Siegal DM, Freedman D, Ansell J. Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review. *J Thromb Thrombolysis.* 2023;55(2):197-202. doi:10.1007/s11239-022-02739-w
3. Polito NB, Kanouse E, Jones CMC, McCann M, Refaai MA, Acquisto NM. Effect of vitamin K administration on rate of warfarin reversal. *Transfusion.* 2019;59(4):1202-1208. doi:10.1111/trf.15146
4. Steiner T, Poli S, Griebel M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. *Lancet Neurol.* 2016;15(6):566-573. doi:10.1016/S1474-4422(16)00110-1
5. Chaudhary R, Singh A, Chaudhary R, et al. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2022;5(11):e2240145. doi:10.1001/jamanetworkopen.2022.40145
6. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. *Ann Intern Med.* 2019;171(11):805-822. doi:10.7326/M19-1795
7. Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. *Gastrointest Endosc.* 2013;78(2):227-239. doi:10.1016/j.gie.2013.04.179
8. Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. *Am J Gastroenterol.* 2022;117(4):542-558. doi:10.14309/ajg.0000000000001627
9. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. *Transfus Med Rev.* 2007;21(1):37-48. doi:10.1016/j.tmr.2006.08.002
10. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a

randomized, plasma-controlled, phase IIIb study. *Circulation*. 2013;128(11):1234-1243. doi:10.1161/CIRCULATIONAHA.113.002283

11. Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. *Lancet*. 2015;385(9982):2077-2087. doi:10.1016/S0140-6736(14)61685-8
12. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053
13. Schulman S, Ritchie B, Nahirniak S, et al. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. *Thromb Res*. 2017;152:44-48. doi:10.1016/j.thromres.2017.02.010
14. Kaatz S, Mahan CE, Nakhle A, et al. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. *Curr Cardiol Rep*. 2017;19(12):124. doi:10.1007/s11886-017-0930-2
15. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *Europace*. 2021;23(10):1612-1676. doi:10.1093/europace/euab065
16. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv*. 2018;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893
17. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e152S-e184S. doi:10.1378/chest.11-2295
18. Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants? *Kardiol Pol*. 2019;77(1):3-11. doi:10.5603/KP.a2018.0197
19. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. *N Engl J Med*. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
20. Elmunzer BJ, Young SD, Inadomi JM, Schoenfeld P, Laine L. Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. *Am J Gastroenterol*. 2008;103(10):2625-2632; quiz 2633. doi:10.1111/j.1572-0241.2008.02070.x

21. Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. *Am J Gastroenterol*. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245
22. Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):620-624. doi:10.1182/asheducation-2016.1.620
23. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis. *Dig Dis Sci*. 2021;66(2):554-566. doi:10.1007/s10620-020-06248-9
24. Tokar JL, Higa JT. Acute Gastrointestinal Bleeding. *Ann Intern Med*. 2022;175(2):ITC17-ITC32. doi:10.7326/AITC202202150
25. Sengupta N, Feuerstein JD, Jairath V, et al. Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline. *Am J Gastroenterol*. 2023;118(2):208-231. doi:10.14309/ajg.0000000000002130
26. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. *Endoscopy*. 2021;53(3):300-332. doi:10.1055/a-1369-5274
27. Sengupta N, Feuerstein JD, Patwardhan VR, et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. *Am J Gastroenterol*. 2015;110(2):328-335. doi:10.1038/ajg.2014.398
28. Majeed A, Wallvik N, Eriksson J, et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. *Thromb Haemost*. 2017;117(3):491-499. doi:10.1160/TH16-07-0498
29. Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. *Chest*. 1998;114(6):1505-1508. doi:10.1378/chest.114.6.1505
30. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. *Chest*. 2017;151(1):127-138. doi:10.1016/j.chest.2016.08.1462
31. Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants. *Hematology Am Soc Hematol Educ Program*. 2015;2015:117-124. doi:10.1182/asheducation-2015.1.117
32. Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). *Biomedicines*. 2021;9(5):445. doi:10.3390/biomedicines9050445

33. ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. *Gastrointest Endosc.* 2016;83(1):3-16. doi:10.1016/j.gie.2015.09.035
34. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy.* 2015;47(10):a1-46. doi:10.1055/s-0034-1393172
35. Oakland K, Chadwick G, East JE, et al. Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. *Gut.* 2019;68(5):776-789. doi:10.1136/gutjnl-2018-317807
36. Chan FKL, Goh KL, Reddy N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. *Gut.* 2018;67(3):405-417. doi:10.1136/gutjnl-2017-315131
37. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
38. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
39. Fernando SM, Qureshi D, Talarico R, et al. Intracerebral Hemorrhage Incidence, Mortality, and Association With Oral Anticoagulation Use: A Population Study. *Stroke.* 2021;52(5):1673-1681. doi:10.1161/STROKEAHA.120.032550
40. Dowlathshahi D, Demchuk AM, Flaherty ML, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. *Neurology.* 2011;76(14):1238-1244. doi:10.1212/WNL.0b013e3182143317
41. Sheth KN, Solomon N, Alhanti B, et al. Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage. *JAMA Neurol.* 2024;81(4):363-372. doi:10.1001/jamaneurol.2024.0221
42. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. *Stroke.* 1997;28(1):1-5. doi:10.1161/01.str.28.1.1
43. Frontera JA, Gordon E, Zach V, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. *Neurocrit Care.* 2014;21(3):397-406. doi:10.1007/s12028-014-9972-0
44. Franchini M, Lippi G. Prothrombin complex concentrates: an update. *Blood Transfus.* 2010;8(3):149-154. doi:10.2450/2010.0149-09

45. Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. *N Engl J Med.* 2024;390(19):1745-1755. doi:10.1056/NEJMoa2313040
46. Xu Y, Siegal DM. Anticoagulant-associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. *J Thromb Haemost.* 2021;19(10):2383-2393. doi:10.1111/jth.15466
47. Van der Wall SJ, Lopes RD, Aisenberg J, et al. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. *Circulation.* 2019;139(6):748-756. doi:10.1161/CIRCULATIONAHA.118.036710
48. Deutsch D, Boustière C, Ferrari E, Albaladejo P, Morange PE, Benamouzig R. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. *Therap Adv Gastroenterol.* 2017;10(6):495-505. doi:10.1177/1756283X17702092
49. Xu Y, Schulman S, Dowlatsahi D, et al. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. *Chest.* 2017;152(1):81-91. doi:10.1016/j.chest.2017.02.009
50. Green L, Tan J, Morris JK, et al. A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). *Haematologica.* 2018;103(4):738-745. doi:10.3324/haematol.2017.182220
51. Milling TJ, Refaai MA, Sengupta N. Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. *Dig Dis Sci.* 2021;66(11):3698-3714. doi:10.1007/s10620-020-06728-y
52. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. *Thromb Res.* 2005;115(6):455-459. doi:10.1016/j.thromres.2004.09.002
53. Karaca MA, Erbil B, Ozmen MM. Use and effectiveness of prothrombin complex concentrates vs fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED. *Am J Emerg Med.* 2014;32(6):660-664. doi:10.1016/j.ajem.2014.02.016
54. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2014;129(23):e521-643. doi:10.1161/CIR.0000000000000031
55. Schulman S, Carrier M, Lee AYY, et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. *Circulation.* 2015;132(3):167-173. doi:10.1161/CIRCULATIONAHA.115.015688
56. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. *Chest.* 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025

57. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. *JAMA Intern Med.* 2019;179(11):1469-1478. doi:10.1001/jamainternmed.2019.2431
58. PRAXBIND (idarucizumab) injection, for intravenous.pdf. Accessed May 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf
59. download.pdf. Accessed May 15, 2024. <https://www.fda.gov/media/113279/download>
60. Martin AC, Benamouzig R, Gouin-Thibault I, Schmidt J. Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion. *Am J Cardiovasc Drugs.* 2023;23(4):407-418. doi:10.1007/s40256-023-00582-9
61. Sewell JH, Williams L, McKnight E, Nguyen A, Sarac M. What is the role of andexanet alfa in the reversal of anticoagulant effects? *JAAPA.* 2021;34(1):8-9. doi:10.1097/01.JAA.0000723956.47623.90
62. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med.* 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051
63. Singh S, Nautiyal A, Belk KW. Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study. *Am J Cardiovasc Drugs.* 2020;20(2):161-168. doi:10.1007/s40256-019-00360-6
64. ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. *Gastrointest Endosc.* 2009;70(6):1060-1070. doi:10.1016/j.gie.2009.09.040
65. Lau JYW, Yu Y, Tang RSY, et al. Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding. *N Engl J Med.* 2020;382(14):1299-1308. doi:10.1056/NEJMoa1912484
66. Sengupta N, Tapper EB, Feuerstein JD. Early Versus Delayed Colonoscopy in Hospitalized Patients With Lower Gastrointestinal Bleeding: A Meta-Analysis. *J Clin Gastroenterol.* 2017;51(4):352-359. doi:10.1097/MCG.0000000000000602
67. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. *Gut.* 1994;35(4):464-466. doi:10.1136/gut.35.4.464
68. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. *Am J Gastroenterol.* 2007;102(2):290-296. doi:10.1111/j.1572-0241.2006.00969.x

69. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. *Gastrointest Endosc.* 2003;58(3):369-373.
70. Nagata N, Sakurai T, Moriyasu S, et al. Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding. *PLoS One.* 2017;12(9):e0183423. doi:10.1371/journal.pone.0183423
71. Zullo A, Hassan C, Radaelli F. Gastrointestinal endoscopy in patients on anticoagulant therapy and antiplatelet agents. *Ann Gastroenterol.* 2017;30(1):7-14. doi:10.20524/aog.2016.0096
72. McRae HL, Militello L, Refaai MA. Updates in Anticoagulation Therapy Monitoring. *Biomedicines.* 2021;9(3):262. doi:10.3390/biomedicines9030262
73. Ho KH, van Hove M, Leng G. Trends in anticoagulant prescribing: a review of local policies in English primary care. *BMC Health Serv Res.* 2020;20(1):279. doi:10.1186/s12913-020-5058-1
74. Tornkvist M, Smith JG, Labaf A. Current evidence of oral anticoagulant reversal: A systematic review. *Thromb Res.* 2018;162:22-31. doi:10.1016/j.thromres.2017.12.003
75. Curtis R, Schweitzer A, van Vlymen J. Reversal of warfarin anticoagulation for urgent surgical procedures. *Can J Anaesth.* 2015;62(6):634-649. doi:10.1007/s12630-015-0366-3
76. Rudasill SE, Liu J, Kamath AF. Revisiting the International Normalized Ratio (INR) Threshold for Complications in Primary Total Knee Arthroplasty: An Analysis of 21,239 Cases. *J Bone Joint Surg Am.* 2019;101(6):514-522. doi:10.2106/JBJS.18.00771
77. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol.* 2017;70(24):3042-3067. doi:10.1016/j.jacc.2017.09.1085
78. Levy JH, van Ryn J, Sellke FW, et al. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. *Ann Surg.* 2021;274(3):e204-e211. doi:10.1097/SLA.0000000000003638
79. Schmidt LE, Hinton MS, Martin ND. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery. *J Pharm Pract.* 2024;37(1):74-79. doi:10.1177/08971900221125516
80. A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure - Full Text View - ClinicalTrials.gov. Accessed May 15, 2024. <https://classic.clinicaltrials.gov/ct2/show/NCT05926349>

81. Shaw JR, Unachukwu U, Cyr J, et al. Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale. *TH Open*. 2023;7(3):e229-e240. doi:10.1055/s-0043-1771300
82. Heuts S, Ceulemans A, Kuiper GJAJM, et al. Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice. *Eur J Cardiothorac Surg*. 2023;64(4):ezad340. doi:10.1093/ejcts/ezad340
83. Thibault N, Morrill AM, Willett KC. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review. *Am J Ther*. 2018;25(3):e333-e338. doi:10.1097/MJT.0000000000000460
84. Giakoumettis D, Alexiou GA, Vrachatis DA, et al. Antithrombotic Treatment Management in Patients with Intracerebral Hemorrhage: Reversal and Restart. *Curr Pharm Des*. 2017;23(9):1392-1405. doi:10.2174/1381612822666161205111459
85. Murthy SB, Gupta A, Merkler AE, et al. Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. *Stroke*. 2017;48(6):1594-1600. doi:10.1161/STROKEAHA.116.016327
86. Kato Y, Hayashi T, Suzuki K, et al. Resumption of Direct Oral Anticoagulants in Patients with Acute Spontaneous Intracerebral Hemorrhage. *J Stroke Cerebrovasc Dis*. 2019;28(10):104292. doi:10.1016/j.jstrokecerebrovasdis.2019.07.008
87. Li YG, Lip GYH. Anticoagulation Resumption After Intracerebral Hemorrhage. *Curr Atheroscler Rep*. 2018;20(7):32. doi:10.1007/s11883-018-0733-y
88. Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. *Neurology*. 2006;66(2):206-209. doi:10.1212/01.wnl.0000194267.09060.77
89. Choi KH, Kim JH, Lee C, et al. Microbleeds and Outcome in Patients With Acute Ischemic Stroke and Atrial Fibrillation Taking Anticoagulants. *Stroke*. 2020;51(12):3514-3522. doi:10.1161/STROKEAHA.120.030300
90. Ji R, Li G, Zhang R, Hou H, Zhao X, Wang Y. Higher risk of deep vein thrombosis after hemorrhagic stroke than after acute ischemic stroke. *J Vasc Nurs*. 2019;37(1):18-27. doi:10.1016/j.jvn.2018.10.006
91. Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. *Thromb Haemost*. 2017;117(7):1448-1454. doi:10.1160/TH16-12-0961
92. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GYH. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. *Circulation*. 2015;132(6):517-525. doi:10.1161/CIRCULATIONAHA.115.015735

93. Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. *Lancet Neurol.* 2021;20(11):907-916. doi:10.1016/S1474-4422(21)00298-2
94. SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. *Lancet Neurol.* 2021;20(10):842-853. doi:10.1016/S1474-4422(21)00264-7
95. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA.* 2015;313(8):824-836. doi:10.1001/jama.2015.0846
96. Park YA, Uhm JS, Pak HN, Lee MH, Joung B. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. *Heart Rhythm.* 2016;13(9):1794-1802. doi:10.1016/j.hrthm.2016.05.016
97. Little D, Chai-Adisaksopha C, Hillis C, et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. *Thromb Res.* 2019;175:102-109. doi:10.1016/j.thromres.2019.01.020
98. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. *Am J Cardiol.* 2014;113(4):662-668. doi:10.1016/j.amjcard.2013.10.044
99. Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. *Arch Intern Med.* 2012;172(19):1484-1491. doi:10.1001/archinternmed.2012.4261
100. Sengupta N, Marshall AL, Jones BA, Ham S, Tapper EB. Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. *Clin Gastroenterol Hepatol.* 2018;16(12):1893-1900.e2. doi:10.1016/j.cgh.2018.05.005
101. Dahiya DS, Kichloo A, Amir R, Wani F. When should antithrombotic therapy be resumed after gastrointestinal bleeding? *Cleve Clin J Med.* 2022;89(11):630-633. doi:10.3949/ccjm.89a.20189
102. Bingzheng X, Jingnan R, Ligang B, Jianping C. The effects of anticoagulant therapy re-initiation after gastrointestinal bleeding: A systematic review and meta-analysis. *J Clin Pharm Ther.* 2021;46(6):1509-1518. doi:10.1111/jcpt.13442
103. Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. *Can J Gastroenterol.* 2006;20(3):171-178. doi:10.1155/2006/859435

104. Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109(4):474-483; quiz 484. doi:10.1038/ajg.2014.19
105. Sami SS, Al-Araji SA, Rangunath K. Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. *Aliment Pharmacol Ther*. 2014;39(1):15-34. doi:10.1111/apt.12527
106. Dar T, Yarlagadda B, Vacek J, Dawn B, Lakkireddy D. Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more. *J Atr Fibrillation*. 2017;10(4):1729. doi:10.4022/jafib.1729
107. Holmes DR, Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. *J Am Coll Cardiol*. 2015;65(24):2614-2623. doi:10.1016/j.jacc.2015.04.025
108. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
109. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2019;74(1):104-132. doi:10.1016/j.jacc.2019.01.011
110. Faroux L, Cruz-González I, Arzamendi D, et al. Incidence, predictors, and clinical impact of bleeding recurrence in patients with prior gastrointestinal bleeding undergoing LAAC. *Pacing Clin Electrophysiol*. 2021;44(7):1216-1223. doi:10.1111/pace.14293
111. Asmarats L, Rodés-Cabau J. Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes. *Circ Cardiovasc Interv*. 2017;10(11):e005359. doi:10.1161/CIRCINTERVENTIONS.117.005359